Anthim, Nyxthracis (previously obiltoxaximab sfl)(obiltoxaximab)
Anthim, Nyxthracis (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Anthim
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Obiltoxaximab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Anthim | obiltoxaximab | Elusys Therapeutics | N-125509 RX | 2016-03-18 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anthim | Biologic Licensing Application | 2021-01-12 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
obiltoxaximab, Anthim, Elusys Therapeutics, Inc. | |||
| 2123-03-18 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OBILTOXAXIMAB |
| INN | obiltoxaximab |
| Description | Obiltoxaximab, sold under the brand name Anthim among others, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1351337-07-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544926 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB05336 |
| UNII ID | 29Z5DNL48C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 191 documents
View more details
Safety
Black-box Warning
Black-box warning for: Anthim
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,247 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more